Literature DB >> 35791880

Tumor necrosis factor alpha delivers exogenous inflammation-related microRNAs to recipient cells with functional targeting capabilities.

Yuechao Zhao1, Tan Zhang2, Xuelian Shen3, Aixue Huang1, Hui Li1, Lin Wang1, Xuemei Liu1, Xuejun Wang4, Xiang Song4, Shengqi Wang4, Jie Dong5, Ningsheng Shao6.   

Abstract

Tumor necrosis factor alpha (TNF-α) is a critical pro-inflammatory cytokine in a wide range of tumors and infectious diseases. This study showed for the first time that TNF-α could specifically bind to certain intracellular or circulating inflammation-related microRNAs both in vitro and in vivo. The binding sites of TNF-α to microRNAs are located at the N-terminal of TNF-α and the 3'-GGUU motif of microRNAs. TNF-α could deliver exogenous unmodified single-stranded microRNAs into recipient cells through the TNF-α receptors (TNFRs) and stabilize them from being degraded by RNase in cells. Exogenous miR-146a or let-7c delivered into HCT116 cells by TNF-α could escape from lysosomes and specifically downregulate their target genes and then affect cell proliferation and migration in vitro, as well as tumorigenesis in vivo. Based on the above findings, the concept of "non-conjugated ligand-mediated RNA delivery (ncLMRD)" was proposed, which may serve as a promising strategy for therapeutic microRNA delivery in the future.
Copyright © 2022 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  RNA binding protein; TNF-α; TNF-α receptor; microRNA delivery; recipient cells

Mesh:

Substances:

Year:  2022        PMID: 35791880      PMCID: PMC9481991          DOI: 10.1016/j.ymthe.2022.06.017

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   12.910


  55 in total

Review 1.  Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level.

Authors:  W Fiers
Journal:  FEBS Lett       Date:  1991-07-22       Impact factor: 4.124

Review 2.  Delivery materials for siRNA therapeutics.

Authors:  Rosemary Kanasty; Joseph Robert Dorkin; Arturo Vegas; Daniel Anderson
Journal:  Nat Mater       Date:  2013-11       Impact factor: 43.841

Review 3.  Cachectin and tumour necrosis factor as two sides of the same biological coin.

Authors:  B Beutler; A Cerami
Journal:  Nature       Date:  1986 Apr 17-23       Impact factor: 49.962

4.  Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma.

Authors:  Jason D Arroyo; John R Chevillet; Evan M Kroh; Ingrid K Ruf; Colin C Pritchard; Donald F Gibson; Patrick S Mitchell; Christopher F Bennett; Era L Pogosova-Agadjanyan; Derek L Stirewalt; Jonathan F Tait; Muneesh Tewari
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-07       Impact factor: 11.205

Review 5.  Targeted delivery systems for oligonucleotide therapeutics.

Authors:  Bo Yu; Xiaobin Zhao; L James Lee; Robert J Lee
Journal:  AAPS J       Date:  2009-03-19       Impact factor: 4.009

6.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

Review 7.  Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics.

Authors:  Yuanyu Huang
Journal:  Mol Ther Nucleic Acids       Date:  2016-12-10

Review 8.  miR-146 and miR-155: Two Key Modulators of Immune Response and Tumor Development.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli; Catherine Labbaye
Journal:  Noncoding RNA       Date:  2017-06-26

9.  Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological diseases.

Authors:  Ahmed M Abdelaal; Andrea L Kasinski
Journal:  NAR Cancer       Date:  2021-07-20

10.  A knowledge-based scoring function for protein-RNA interactions derived from a statistical mechanics-based iterative method.

Authors:  Sheng-You Huang; Xiaoqin Zou
Journal:  Nucleic Acids Res       Date:  2014-01-29       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.